XTSE
CRDL
Market cap149mUSD
Oct 08, Last price
1.85CAD
1D
0.00%
1Q
28.47%
IPO
-60.22%
Name
Cardiol Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
23.85%
Rev. gr., 5y
%
Revenues
0
Net income
-34m
L-7.79%
CFO
-24m
L-4.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Key people
Guillermo Torre-Amione
Independent Chairman of the Board · since 2021
Bernard Lim
Chief Operating Officer · since 2020
Andrew Hamer
Chief Medical Officer, Head of Research and Development · since 2021
David Elsley
President, Chief Executive Officer, Director · since 2017
Christopher Waddick
Chief Financial Officer, Corporate Secretary, Director · since 2022
Independent Director · since 2022
Teri Loxam
Independent Director · since 2022
Peter Pekos
Independent Director · since 2017
Colin Stott
Independent Director · since 2019
Michael Willner
Independent Director · since 2021
Headquarters & legal address
2265 Upper Middle Road East, Suite 602
Oakville L6H 0G5
CA
Oakville L6H 0G5
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||